Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Raw Materials (2016 - 2024)

Corcept Therapeutics (CORT) has disclosed Raw Materials for 10 consecutive years, with $704000.0 as the latest value for Q1 2024.

  • Quarterly Raw Materials changed N/A to $704000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $704000.0 through Mar 2024, changed N/A year-over-year, with the annual reading at $1.7 million for FY2020, 21.31% up from the prior year.
  • Raw Materials hit $704000.0 in Q1 2024 for Corcept Therapeutics, down from $1.7 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.7 million in Q4 2020 to a low of $704000.0 in Q1 2024.